Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Tam et al report long-term data from 300 CLL patients treated with the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. Complete and overall response rates were 72% and 95%, respectively. The median time to progression was 80 months, and six-year overall survival was 77%. Late infection occurred in 10% after the first year of treatment, and almost 19% had persistent cytopenias after treatment. After adjusting for pre-treatment factors, FCR was associated with prolonged survival compared to other fludarabine regimens for initial treatment at the same center. The high activity and prolonged remissions suggest FCR as an excellent front-line regimen for CLL in select patients.

Fludarabine, Cyclophosphamide, Rituximab for CLL